Literature DB >> 19699527

IgE-binding properties and selectivity of peptide mimics of the FcvarepsilonRI binding site.

Annamaria Sandomenico1, Simona M Monti, Daniela Marasco, Nina Dathan, Rosanna Palumbo, Michele Saviano, Menotti Ruvo.   

Abstract

FcvarepsilonRIalpha found on the surface of mast cells and basophiles mediates allergic diseases, anaphylaxis and asthma through binding of IgE. Disrupting this interaction with anti-IgE mAbs has proven an efficient approach to control these diseases. The crystallographic structure of the complex formed between the IgE-Fc and FcvarepsilonRIalpha extracellular domain has shown that recognition is mediated by residues in the second Ig-like domain of the receptor (D2) and in the loop connecting the D1 and D2 domains. In an attempt to obtain specific IgE antagonists, we have designed and prepared a polypeptide named IgE-Trap that partially reproduces the IgE receptor-binding sites and binds with micromolar affinity to soluble IgE. The polypeptide contains loops C'-E [residues 129-134] and F-G [residues 151-161] from the D2 domain joined by a linker, and loop B-C [residues 110-113]. Peptide binding to IgE has been assessed by SPR analyses and the data fit with a biphasic model of interaction, in agreement with the two-site mechanism reported for the native receptor. The polypeptide binds to immobilized IgE in a dose-dependent manner with a K(D) estimated to be around 6muM, while it does not recognize IgG nor IgA. Polypeptide sub-domains involved in IgE binding have also been defined, showing that loop C'-E connected to loop B-C, but also the isolated loop B-C alone suffice to bind immunoglobulins E with high selectively though with reduced affinity compared to IgE-Trap. ELISA and cytometric assays on RBL2H3 cells demonstrate that the interacting peptides are able to displace the binding of IgE to receptor, confirming affinity and specificity of these ligands and suggesting a potential application as modulators of disorders associated with inappropriate IgE production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699527     DOI: 10.1016/j.molimm.2009.07.025

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  A comparative structural and bioanalytical study of IVIG clinical lots.

Authors:  Annamaria Sandomenico; Valeria Severino; Angela Chambery; Annalia Focà; Giuseppina Focà; Claudio Farina; Menotti Ruvo
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

2.  An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis.

Authors:  Joseph S Zhou; Annamaria Sandomenico; Valeria Severino; Oliver T Burton; Alanna Darling; Hans C Oettgen; Menotti Ruvo
Journal:  Mol Biosyst       Date:  2013-11

Review 3.  Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.

Authors:  Hans C Oettgen
Journal:  J Allergy Clin Immunol       Date:  2016-06       Impact factor: 10.793

Review 4.  IgE and mast cells in allergic disease.

Authors:  Stephen J Galli; Mindy Tsai
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 5.  The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils.

Authors:  Joana Vitallé; Iñigo Terrén; Ane Orrantia; Agurtzane Bilbao; Pedro M Gamboa; Francisco Borrego; Olatz Zenarruzabeitia
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

6.  Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals.

Authors:  John D Eicher; Nathalie Chami; Tim Kacprowski; Akihiro Nomura; Ming-Huei Chen; Lisa R Yanek; Salman M Tajuddin; Ursula M Schick; Andrew J Slater; Nathan Pankratz; Linda Polfus; Claudia Schurmann; Ayush Giri; Jennifer A Brody; Leslie A Lange; Ani Manichaikul; W David Hill; Raha Pazoki; Paul Elliot; Evangelos Evangelou; Ioanna Tzoulaki; He Gao; Anne-Claire Vergnaud; Rasika A Mathias; Diane M Becker; Lewis C Becker; Amber Burt; David R Crosslin; Leo-Pekka Lyytikäinen; Kjell Nikus; Jussi Hernesniemi; Mika Kähönen; Emma Raitoharju; Nina Mononen; Olli T Raitakari; Terho Lehtimäki; Mary Cushman; Neil A Zakai; Deborah A Nickerson; Laura M Raffield; Rakale Quarells; Cristen J Willer; Gina M Peloso; Goncalo R Abecasis; Dajiang J Liu; Panos Deloukas; Nilesh J Samani; Heribert Schunkert; Jeanette Erdmann; Myriam Fornage; Melissa Richard; Jean-Claude Tardif; John D Rioux; Marie-Pierre Dube; Simon de Denus; Yingchang Lu; Erwin P Bottinger; Ruth J F Loos; Albert Vernon Smith; Tamara B Harris; Lenore J Launer; Vilmundur Gudnason; Digna R Velez Edwards; Eric S Torstenson; Yongmei Liu; Russell P Tracy; Jerome I Rotter; Stephen S Rich; Heather M Highland; Eric Boerwinkle; Jin Li; Ethan Lange; James G Wilson; Evelin Mihailov; Reedik Mägi; Joel Hirschhorn; Andres Metspalu; Tõnu Esko; Caterina Vacchi-Suzzi; Mike A Nalls; Alan B Zonderman; Michele K Evans; Gunnar Engström; Marju Orho-Melander; Olle Melander; Michelle L O'Donoghue; Dawn M Waterworth; Lars Wallentin; Harvey D White; James S Floyd; Traci M Bartz; Kenneth M Rice; Bruce M Psaty; J M Starr; David C M Liewald; Caroline Hayward; Ian J Deary; Andreas Greinacher; Uwe Völker; Thomas Thiele; Henry Völzke; Frank J A van Rooij; André G Uitterlinden; Oscar H Franco; Abbas Dehghan; Todd L Edwards; Santhi K Ganesh; Sekar Kathiresan; Nauder Faraday; Paul L Auer; Alex P Reiner; Guillaume Lettre; Andrew D Johnson
Journal:  Am J Hum Genet       Date:  2016-06-23       Impact factor: 11.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.